Herpes zoster

Wilson, Denise

doi:10.1097/01.npr.0000445781.37062.16

The Nurse Practitioner

2014

DOI: 10.1097/01.npr.0000445781.37062.16

|View full text |Cite

Herpes zoster

Denise Wilson¹

Abstract: This article discusses the incidence, epidemiology, clinical presentation, diagnosis, and treatment of herpes zoster, complications such as postherpetic neuralgia, and prevention through vaccination. Information on vaccine cost and insurance coverage is provided as well as two case studies illustrating various clinical presentations.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2014

2019

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to age, an individual's immune system is an essential factor in reactivation of the varicella zoster virus (11). Previous findings have suggested that the frequencies of HZ events are several times higher among patients with autoimmune or inflammatory (AI) diseases, such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), as compared to patients without AI diseases (12).…”

mentioning

confidence: 99%

Risk of Herpes Zoster in Autoimmune and Inflammatory Diseases: Implications for Vaccination

Yun

Yang

Chen

et al. 2016

Arthritis & Rheumatology

173

125

View full text Add to dashboard Cite

Objective. The herpes zoster (HZ) vaccine is recommended for adults in the US ages ‡60 years who do not have weakened immune systems. It is unclear how the risk of HZ varies according to age and disease conditions in younger patients with autoimmune or inflammatory (AI) diseases. This study was undertaken to evaluate the age-stratified incidence of HZ in patients with AI diseases as compared to older adults for whom the HZ vaccine is currently recommended by the US Centers for Disease Control and Prevention.Methods. Using linked data obtained from patients who were insured by US commercial and government health care plans during the period 2007-2010, 7 cohorts of patients with AI diseases were assembled: systemic lupus erythematosus (SLE), inflammatory bowel disease (IBD), rheumatoid arthritis (RA), psoriatic arthritis (PsA), psoriasis (PsO), ankylosing spondylitis (AS), and gout. Two comparator cohorts were also assembled as controls: adult patients with diabetes and adult subjects without AI diseases or diabetic conditions. HZ was identified using diagnostic codes. Age-specific incidence rates (IRs) of HZ were calculated and compared to the IRs of HZ in control subjects ages 61-70 years who were without AI diseases or diabetic conditions.Results. After review of the linked data, the following number of enrollment periods were identified: 8,395 for patients with SLE, 7,916 for patients with IBD, 50,646 for patients with RA, 2,629 for patients with PsA, 4,299 for patients with PsO, 1,019 for patients with AS, 58,934 for patients with gout, 214,631 for control patients with diabetes, and 330,727 for control subjects without AI diseases and diabetic conditions. The respective highest and lowest IRs of HZ during the study were 19.9 per 1,000 person-years in the SLE cohort and 6.8 per 1,000 person-years in the gout cohort, as compared to an IR of 5.3 per 1,000 person-years in control subjects without AI diseases or diabetic conditions. The age-specific IRs of HZ in patients with RA and those with SLE ages ‡40 years were 1.5-2 times greater than those observed in

show abstract

mentioning

confidence: 99%

Risk of Herpes Zoster in Autoimmune and Inflammatory Diseases: Implications for Vaccination

Yun

Yang

Chen

et al. 2016

Arthritis & Rheumatology

173

125

View full text Add to dashboard Cite

show abstract

The risk of herpes zoster among patients with ankylosing spondylitis: A population‐based cohort study in Taiwan

et al. 2019

View full text Add to dashboard Cite

Objectives The incident rate of herpes zoster (HZ) is higher in some autoimmune diseases; however the relationship of HZ and ankylosing spondylitis (AS) is still unclear. This research aims to determine the incidence of HZ in Taiwan AS patients. Methods This study included 2819 AS patients and 11 276 non‐AS controls between 2003 and 2013. All participants were selected from the Longitudinal Health Insurance Database 2000 Taiwan. The endpoint was diagnosis of HZ by International Classification of Diseases, Ninth Revision, Clinical Modification coding for at least 3 outpatient visits or one admission until the end of 2013. We used Chi‐square test, Cox proportional hazard models and a Kaplan‐Meier analysis to calculate the hazards ratio (HR), disease‐free survival and incidental density of HZ. Subgroup analysis and sensitivity tests were also done. Results Comorbidities such as chronic urticaria, inflammatory bowel disease, thyroid disorders, hypertension, diabetes mellitus, hyperlipidemia, coronary artery disease, cerebrovascular accident, were higher in patients with AS than that in controls. Patients age ≥60 or comorbid disease such as thyroid disorders or cancer had a higher HR of HZ; the adjusted HRs were 2.273 (95% CI 1.314‐3.931), 1.577 (95% CI 1.008‐2.466) and 1.855 (95% CI 1.248‐2.758) respectively, on multivariable modeling. The crude HR for HZ among AS patient was 1.178 (95% CI 0.953‐1.455, P > 0.05), and the adjust HZ was 1.070 (95% CI 0.835‐1.371, P > 0.05), compared to non‐AS controls. Conclusions There is no difference in incidence rate of HZ between Taiwan AS patients and non‐AS controls. Among AS patients, age and cancer were major risk factors for incidental HZ.

show abstract

The burden of disease of Herpes Zoster in Tuscany

Levi

Bellini

Capecchi

et al. 2014

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Herpes zoster

Cited by 3 publications

References 17 publications

Risk of Herpes Zoster in Autoimmune and Inflammatory Diseases: Implications for Vaccination

Risk of Herpes Zoster in Autoimmune and Inflammatory Diseases: Implications for Vaccination

The risk of herpes zoster among patients with ankylosing spondylitis: A population‐based cohort study in Taiwan

The burden of disease of Herpes Zoster in Tuscany

Contact Info

Product

Resources

About